Page results
-
UCLH has recruited the first participant for a new UK based study for Parkinson’s Disease (PD). The ASPro-PD study is testing whether treatment with a drug called ambroxol is associated with an improvement in motor and non-motor function compared with placebo.
-
UCLH has declared a climate and health emergency, and has published a 10-point climate action plan to reach net zero carbon dioxide emissions by 2031.
-
Information about our UCLH Charity, charity funds and associated charities.
-
Read more about the NHS Staff Survey 2024 - we’re the top acute trust to work at for third year running!
-
Christmas is an exciting time even if it will be a bit different for us all this year. We might be spending more time inside, making us less active than usual for this time of year. However, it is still a good time to relax and enjoy some Christmas treats.
-
CAMLIS is the Royal London Hospital for Integrated Medicine (RLHIM) Complementary and Alternative Medicine Information and Library Service and is situated on the ground floor of the hospital.
-
Researchers at UCLH have begun a study which could set the foundations for how booster COVID-19 vaccinations are delivered in the future.
-
This page explains what patient-initiated follow-up (PIFU) involves after your treatment for endometrial (uterine or womb) cancer.
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
While you're pregnant you will have a nominated professional lead which will be a midwife or an obstetrician.
File results
-
FOI/2022/0171 - Consultant-led Referral to Treatment (RTT), outpatients and Patient Initiated Follow-up (PIFU)
-
FOI/2022/0172 - Contraceptive pill data
-
FOI/2022/0174 - Clinical systems for bed management, diagnostic reporting, discharge letters, and integration platform systems
-
FOI/2022/0177 - Assessment and treatment unit for mental health and learning disabilities
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients
-
FOI/2022/0193 - Drug treatment for breast cancer